Menu

What drives negative perceptions of biosimilars?

Biosimilars/Research | Posted 23/07/2021 comments 0
11 AA010165

A study of patients taking biological drugs in New Zealand identifies a number of attributes associated with negative perceptions of biosimilars, including being female, seeking information online,...

More >
LATIN AMERICAN FORUM
Checklist V14A17
UK’s MHRA updates its guidance on licensing biosimilars
Posted 16/07/2021

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has updated its gui...

Rheumatology.org V13H09
Prices for arthritis biologicals in Latin America
Posted 21/06/2021

Analysis of the prices of biological and biosimilar drugs used to treat rheumatoid arth...

20 AA010933
Position of CAEME on biological and biosimilar drugs in Argentina
Posted 02/07/2021

The pharmaceutical companies that comprise the Argentine Chamber of Medicinal Products...

Home/Non‐Biological Complex Drugs
Liposome V15L11

FDA issues final guidance on liposome drug products

Posted 27/04/2018 comments 0

On 4 April 2018, the US Food and Drug Administration (FDA) issued a new draft guidance...

More >

Generics

Generics applications under review by EMA – July 2021
Generics/General | Posted 23/07/2021
The generics market in Brazil
Generics/Research | Posted 16/07/2021
US generic approvals for Acrux and Cipla
Generics/News | Posted 16/07/2021
Laws on packaging, substitution and prescription of generics in Brazil
Generics/Research | Posted 09/07/2021

Biosimilars

What drives negative perceptions of biosimilars?
Biosimilars/Research | Posted 23/07/2021
China approves sintilimab plus bevacizumab copy biological Byvasda
Biosimilars/News | Posted 23/07/2021
Clinical trials begin for ustekinumab biosimilars
Biosimilars/Research | Posted 23/07/2021
Biosimilars as a sustainable alternative for complex diseases
Biosimilars/General | Posted 23/07/2021

Sign up today for the weekly briefing on the latest developments in generic and biosimilar medicines!

Yes, I want to receive email newsletters. I can unsubscribe at any time. Please note our Privacy Policy.